Biotechnology company Amgen announced Thursday it is investing $2.7 billion in BeiGene, taking a 20.5% stake in the Chinese biotech firm, valuing it at roughly $13.5 billion.
Under the all-cash deal, Amgen will pay BeiGene shareholders $174.85 per share, a 2…
